Navigation Links
Study Weighs Cost, Benefit of Gene Tests Before Warfarin Rx
Date:1/20/2009

The screens resulted in better patient outcomes but at high price, researchers say

TUESDAY, Jan. 20 (HealthDay News) -- Genetic testing isn't cost-effective in guiding initial dosing of the blood thinner warfarin in patients with atrial fibrillation (a type of abnormal heart rhythm), a University of Cincinnati study finds.

Warfarin is used to prevent blood clotting in these patients. In 2007, the U.S. Food and Drug Administration changed the labeling for warfarin to suggest that doctors consider genetic testing before using the blood thinner.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," study lead investigator Dr. Mark Eckman, professor of medicine, explained in a UC news release.

"The idea behind genetic testing -- also known as pharmacogenetic-guided dosing -- is to help guide the initial, and possibly lower, dose of warfarin for patients," Eckman said. "The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

He and his colleagues analyzed the findings of three published studies and then created a model to estimate the cost-effectiveness of genetic testing.

They found that genotype-guided dosing did result in better patient outcomes but at a cost of more than $170,000 per quality-adjusted life year gained. They also found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective. The findings were published in the Jan. 20 issue of the journal Annals of Internal Medicine.

The researchers concluded that genotype-guiding dosing is cost effective if it:

  • is used for patients at high risk for hemorrhage;
  • prevents more than 32 percent of major bleeding events;
  • is available within 24 hours;
  • costs less than $200.

"This could be accomplished if testing were done in-house, at lower cost and without delays," said Eckman. Currently, most of these tests have to be sent to outside laboratories, which can lead to increased cost and treatment delays.

More information

The U.S. Agency for Healthcare Research and Quality has more about warfarin.



-- Robert Preidt



SOURCE: University of Cincinnati, news release, Jan. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study compares 2 nonsurgical treatments for reflux disease
2. Study examines racial disparities in survival among patients diagnosed with lung cancer
3. Study shows rise in antibiotic resistant pediatric head and neck infections
4. Study: Growth in research comes at a steep price
5. National Childrens Study Begins Recruiting
6. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
7. Tufts receives NIH grant to study obesity prevention in new immigrants
8. New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage
9. 2009 Most Wired Survey and Benchmarking Study Opens Today
10. Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
11. Newer Antipsychotics Pose Cardiac Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Weighs Cost, Benefit of Gene Tests Before  Warfarin Rx
(Date:4/28/2016)... ... April 28, 2016 , ... ... solutions, announces today the availability of its latest software release, NetZoomDC 14.5. ... management and optimization, providing new analytical capabilities that assess complex capacity factors ...
(Date:4/28/2016)... ... 2016 , ... Amada Senior Care, premier provider of non-medical in-home care and ... San Antonio West location. Prior to entering the senior care industry, Amada franchise partner ... Amada San Antonio West will take place on Friday, April 29th. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Anzu®, ... announced a new Residency Education & Collaboration Platform for hospitals and medical ... and a host of collaboration tools designed to improve patient outcomes through ...
(Date:4/28/2016)... ... April 28, 2016 , ... April, 28, ... Top Doc in Physical Medicine and Rehabilitation by Philadelphia Magazine. , Philadelphia Magazine’s ... by randomly surveying physicians and medical leadership across the country. These select individuals ...
(Date:4/28/2016)... ... 2016 , ... SyncDog, Inc. , the leading ISV ... workstation suite, SentinelSecure™, at MobileIron’s 6th annual Mobile First Conference in San Francisco, ... 6th Mobile First Conference and will feature immersive training, collaboration, and connections with ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
(Date:4/26/2016)... April 26, 2016 Bayer AG ... interest, taxes, depreciation and amortization. The earnings are the ... multinational,s best-selling drugs Xarelto and Eylea, drugs Bayer is ... Xarelto,s patent expiration date was extended by four years ... market is expected to reach a value of ...
(Date:4/26/2016)... YORK , April 26, 2016 /PRNewswire/ ... report "Global Microbial identification Market Size, Share, ... - Industry Insights by Product (Consumables, Instruments ... Method and Genotypic Method), by Application (Diagnostic ... and Environmental Application) and by End User ...
Breaking Medicine Technology: